Matches in Nanopublications for { ?s ?p "[The PI3K/mTOR dual inhibitor P7170 demonstrates potent activity against endocrine-sensitive and endocrine-resistant ER+ breast cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en ?g. }
Showing items 1 to 16 of
16
with 100 items per page.
- assertion description "[The PI3K/mTOR dual inhibitor P7170 demonstrates potent activity against endocrine-sensitive and endocrine-resistant ER+ breast cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- assertion description "[The PI3K/mTOR dual inhibitor P7170 demonstrates potent activity against endocrine-sensitive and endocrine-resistant ER+ breast cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- assertion description "[The PI3K/mTOR dual inhibitor P7170 demonstrates potent activity against endocrine-sensitive and endocrine-resistant ER+ breast cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- assertion description "[The PI3K/mTOR dual inhibitor P7170 demonstrates potent activity against endocrine-sensitive and endocrine-resistant ER+ breast cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- assertion description "[The PI3K/mTOR dual inhibitor P7170 demonstrates potent activity against endocrine-sensitive and endocrine-resistant ER+ breast cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- assertion description "[The PI3K/mTOR dual inhibitor P7170 demonstrates potent activity against endocrine-sensitive and endocrine-resistant ER+ breast cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- assertion description "[The PI3K/mTOR dual inhibitor P7170 demonstrates potent activity against endocrine-sensitive and endocrine-resistant ER+ breast cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- assertion description "[The PI3K/mTOR dual inhibitor P7170 demonstrates potent activity against endocrine-sensitive and endocrine-resistant ER+ breast cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- NP1246574.RATPEOR1P-7Tt5pw191v8ObJWUBKA3R0lcxOuHpJM8S1k130_assertion description "[The PI3K/mTOR dual inhibitor P7170 demonstrates potent activity against endocrine-sensitive and endocrine-resistant ER+ breast cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1246574.RATPEOR1P-7Tt5pw191v8ObJWUBKA3R0lcxOuHpJM8S1k130_provenance.
- NP1246584.RAZO1a6f6s28zYNtYP97DaJuXiXJ6Jrbt2pC-AFEcqaEc130_assertion description "[The PI3K/mTOR dual inhibitor P7170 demonstrates potent activity against endocrine-sensitive and endocrine-resistant ER+ breast cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1246584.RAZO1a6f6s28zYNtYP97DaJuXiXJ6Jrbt2pC-AFEcqaEc130_provenance.
- NP1246585.RAaIZiGv-6TO0JuMIgikbYWa1Zsjs-36Y7sarYxiUThuA130_assertion description "[The PI3K/mTOR dual inhibitor P7170 demonstrates potent activity against endocrine-sensitive and endocrine-resistant ER+ breast cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1246585.RAaIZiGv-6TO0JuMIgikbYWa1Zsjs-36Y7sarYxiUThuA130_provenance.
- NP1246569.RAiDfkI6SMu9IjoQnOY3V60X7d7TsWdBy7uQ_7XbUSrUU130_assertion description "[The PI3K/mTOR dual inhibitor P7170 demonstrates potent activity against endocrine-sensitive and endocrine-resistant ER+ breast cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1246569.RAiDfkI6SMu9IjoQnOY3V60X7d7TsWdBy7uQ_7XbUSrUU130_provenance.
- NP1246583.RAGFjSNetpSRM-B2uXHn7C-Tr9sFQePBJXnESX9xl59JU130_assertion description "[The PI3K/mTOR dual inhibitor P7170 demonstrates potent activity against endocrine-sensitive and endocrine-resistant ER+ breast cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1246583.RAGFjSNetpSRM-B2uXHn7C-Tr9sFQePBJXnESX9xl59JU130_provenance.
- NP1246572.RAzAt2x0TWNpa_D-W8Y6iCxuNulU3uM4TlegCuLZpP-nY130_assertion description "[The PI3K/mTOR dual inhibitor P7170 demonstrates potent activity against endocrine-sensitive and endocrine-resistant ER+ breast cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1246572.RAzAt2x0TWNpa_D-W8Y6iCxuNulU3uM4TlegCuLZpP-nY130_provenance.
- NP1246575.RA_3H6C8siXO-QVRPCDF_FlqkVxA3uWWZOCP46zw087dY130_assertion description "[The PI3K/mTOR dual inhibitor P7170 demonstrates potent activity against endocrine-sensitive and endocrine-resistant ER+ breast cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1246575.RA_3H6C8siXO-QVRPCDF_FlqkVxA3uWWZOCP46zw087dY130_provenance.
- NP1246578.RA9ym4k6dVuzu2q3hsdg0hhqPpuZBaW9IXiyMD901FCqk130_assertion description "[The PI3K/mTOR dual inhibitor P7170 demonstrates potent activity against endocrine-sensitive and endocrine-resistant ER+ breast cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1246578.RA9ym4k6dVuzu2q3hsdg0hhqPpuZBaW9IXiyMD901FCqk130_provenance.